Drugs that contain Glycopyrrolate; Neostigmine Methylsulfate
1. Prevduo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456354 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(14 years from now) | |
| US11110054 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(14 years from now) | |
Market Authorisation Date: 23 February, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
PREVDUO family patents
